Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Super-cold container firm va-Q-tec expands to meet COVID-19 vaccine demand

Tue, 24th Nov 2020 11:57

By Ilona Wissenbach

FRANKFURT, Nov 24 (Reuters) - Cold-storage specialist
va-Q-tec is significantly expanding its fleet of 2,500
rental containers to meet growing demand to transport COVID-19
vaccines that need to be kept as low as -70 degrees Celsius
(-94°F), its chief executive said.

The German company is in talks with all the major
pharmaceutical manufacturers of COVID-19 vaccines, CEO Joachim
Kuhn told Reuters in an interview.

Kuhn said the company would "significantly expand" its fleet
of rental containers in the coming year. He did not specify how
many extra containers were planned, though said it would not be
to the extent of doubling the fleet.

Va-Q-tec is among a handful of high-end packaging providers
who have found themselves in high demand as drugmakers and
logistics firms prepares to transport such shots around the
world. Its shares have risen by 230% this year, valuing the
company at around $690 million.

The company's turnover has increased by 30% annually over
the past 10 years. "We expect this growth to continue in a
similar form," said the CEO, adding that global vaccine
distribution might take several years.

"We are carefully increasing the number. With the market
growing by more than 10% per year, we are not afraid that we
will be left sitting on empty containers after corona."

The Würzburg-based company completed a 25 million Swiss
franc ($27.4 million) bond issue on Monday to help fund its
expansion plans.

It manufactures "passive" containers, which use dry ice to
keep the contents at ultra-cold temperatures for up to five or
six days, as opposed to "active" containers that also use
electric motors for cooling.

The vaccine candidate developed by Pfizer and
BioNTech, which uses mRNA technology, needs to be kept at about
-70 degrees Celsius, colder than the offerings from Moderna Inc
and AstraZeneca PLC.

Kuhn said va-Q-tec had contracts with the world's 20 largest
airlines and major freight-forwarders. He said intercontinental
transport with cargo flights was expected to be less of a
problem than last-mile distribution on the road, given there was
experience in transporting super-cold goods by air.

"To meet the demand for dry ice is not a big problem in our
latitudes with sufficient regional production," Kuhn said. "It
will be a challenge in countries that do not have this
infrastructure in Africa, Latin America or Russia."
(Reporting by Ilona Wissenbach, Reuters TV; Writing by Jamie
Freed; Editing by Pravin Char)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.